Bionime Crescita futura

Future criteri di controllo 0/6

We currently don't have sufficient analyst coverage to forecast growth and revenue for Bionime.

Informazioni chiave

n/a

Tasso di crescita degli utili

n/a

Tasso di crescita dell'EPS

Medical Equipment crescita degli utili	23.0%
Tasso di crescita dei ricavi	n/a
Rendimento futuro del capitale proprio	n/a
Copertura analitica	None
Ultimo aggiornamento	n/a

Aggiornamenti recenti sulla crescita futura

Recent updates

Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Mar 23

Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Mar 05

Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

Feb 15

Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

Feb 01

How Has Bionime (TPE:4737) Allocated Its Capital?

Jan 19

A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

Jan 06

A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Dec 22

Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

Dec 09

Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

Nov 24

In questa sezione di solito presentiamo le proiezioni di crescita dei ricavi e degli utili basate sulle stime di consenso degli analisti professionisti per aiutare gli investitori a capire la capacità della società di generare profitti. Tuttavia, poiché Bionime non ha fornito dati sufficienti sul passato e non ha previsioni degli analisti, i suoi utili futuri non possono essere calcolati in modo affidabile estrapolando i dati passati o utilizzando le previsioni degli analisti.

Si tratta di una situazione piuttosto rara, dato che il 97% delle società coperte da SimplyWall St dispone di dati finanziari passati.

Previsioni di crescita degli utili e dei ricavi

TWSE:4737 - Stime future degli analisti e dati finanziari passati (TWD Millions )
Data	Ricavi	Guadagni	Flusso di cassa libero	Liquidità dell'operazione	Avg. Numero di analisti
6/30/2024	1,858	-40	-308	101	N/A
3/31/2024	1,809	7	-305	95	N/A
12/31/2023	1,756	6	-238	203	N/A
9/30/2023	1,863	22	-163	297	N/A
6/30/2023	2,002	43	-109	284	N/A
3/31/2023	2,150	72	26	393	N/A
12/31/2022	2,211	91	-171	142	N/A
9/30/2022	2,091	95	-189	91	N/A
6/30/2022	2,023	115	-139	129	N/A
3/31/2022	1,862	89	-208	84	N/A
12/31/2021	1,850	87	-15	270	N/A
9/30/2021	1,879	101	2	254	N/A
6/30/2021	1,832	111	-58	205	N/A
3/31/2021	1,779	83	-62	204	N/A
12/31/2020	1,669	62	-79	218	N/A
9/30/2020	1,913	73	-20	270	N/A
6/30/2020	1,951	38	-4	247	N/A
3/31/2020	2,162	91	248	456	N/A
12/31/2019	2,173	106	267	406	N/A
9/30/2019	2,043	112	117	243	N/A
6/30/2019	2,113	132	55	208	N/A
3/31/2019	1,986	121	-98	64	N/A
12/31/2018	2,007	128	-47	122	N/A
9/30/2018	1,962	114	2	164	N/A
6/30/2018	1,842	135	40	166	N/A
3/31/2018	1,821	137	N/A	99	N/A
12/31/2017	1,820	150	N/A	30	N/A
9/30/2017	1,771	174	N/A	134	N/A
6/30/2017	1,780	181	N/A	275	N/A
3/31/2017	1,791	192	N/A	420	N/A
12/31/2016	1,740	179	N/A	458	N/A
9/30/2016	1,654	143	N/A	441	N/A
6/30/2016	1,637	119	N/A	373	N/A
3/31/2016	1,571	91	N/A	228	N/A
12/31/2015	1,610	99	N/A	200	N/A
9/30/2015	1,634	101	N/A	271	N/A
6/30/2015	1,591	82	N/A	305	N/A
3/31/2015	1,571	72	N/A	354	N/A
12/31/2014	1,525	54	N/A	360	N/A
9/30/2014	1,446	22	N/A	272	N/A
6/30/2014	1,459	43	N/A	148	N/A
3/31/2014	1,536	72	N/A	165	N/A
12/31/2013	1,561	90	N/A	129	N/A

Previsioni di crescita futura degli analisti

Guadagni vs tasso di risparmio: Insufficient data to determine if 4737's forecast earnings growth is above the savings rate (1%).

Guadagni vs Mercato: Insufficient data to determine if 4737's earnings are forecast to grow faster than the TW market

Guadagni ad alta crescita: Insufficient data to determine if 4737's earnings are expected to grow significantly over the next 3 years.

Ricavi vs Mercato: Insufficient data to determine if 4737's revenue is forecast to grow faster than the TW market.

Ricavi ad alta crescita: Insufficient data to determine if 4737's revenue is forecast to grow faster than 20% per year.

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

ROE futuro: Insufficient data to determine if 4737's Return on Equity is forecast to be high in 3 years time

Bionime Crescita futura

Future criteri di controllo 0/6

Informazioni chiave

Aggiornamenti recenti sulla crescita futura

Price target increased to NT$85.00

Recent updates

Bionime Corporation to Report Q3, 2024 Results on Nov 06, 2024

Second quarter 2024 earnings: EPS and revenues miss analyst expectations

Bionime Corporation to Report Q2, 2024 Results on Aug 08, 2024

Bionime (TWSE:4737) Is Reducing Its Dividend To NT$2

Upcoming dividend of NT$2.00 per share

Bionime (TWSE:4737) Will Pay A Smaller Dividend Than Last Year

Dividend reduced to NT$2.00

First quarter 2024 earnings: EPS and revenues miss analyst expectations

Bionime Corporation to Report Q1, 2024 Results on May 09, 2024

Full year 2023 earnings released: EPS: NT$0.10 (vs NT$1.50 in FY 2022)

Bionime Corporation, Annual General Meeting, Jun 28, 2024

New minor risk - Earnings quality

Bionime Corporation Announces TFDA Approval for iFree Continuous Glucose Monitoring System Second-Class Medical Device License

Bionime Corporation Announces Resignation of Marvin Wu as Globle Sales Division Officer

Second quarter 2023 earnings released: EPS: NT$0.17 (vs NT$0.65 in 2Q 2022)

Bionime Corporation Announces Appointment of Aling Lai as New Member to the Remuneration Committee

Upcoming dividend of NT$2.10 per share at 2.7% yield

Bionime Corporation Appoints Aling Lai as Additional Member of Audit Committee

Full year 2022 earnings: EPS misses analyst expectations

Price target increased to NT$85.00

Less than half of directors are independent

Third quarter 2022 earnings: EPS misses analyst expectations

Bionime Corporation Got A Taiwan Clinical Study Report for Continuous Glucose Monitoring System

Second quarter 2022 earnings released: EPS: NT$0.65 (vs NT$0.22 in 2Q 2021)

Less than half of directors are independent

Upcoming dividend of NT$2.00 per share

Bionime Corporation Announces Members of the First Order Audit Committee of the Company

Less than half of directors are independent

First quarter 2022 earnings: EPS exceeds analyst expectations while revenues lag behind

Insufficient new directors

Full year 2021 earnings: EPS and revenues miss analyst expectations

Bionime Corporation Announces Replacement of the Representative of the Its Institutional Director

Third quarter 2021 earnings released: EPS NT$0.51 (vs NT$0.68 in 3Q 2020)

Second quarter 2021 earnings released: EPS NT$0.22 (vs NT$0.26 loss in 2Q 2020)

Upcoming dividend of NT$2.06 per share

First quarter 2021 earnings released: EPS NT$0.20 (vs NT$0.14 loss in 1Q 2020)

These Return Metrics Don't Make Bionime (TPE:4737) Look Too Strong

Looking For Steady Income For Your Dividend Portfolio? Is Bionime Corporation (TPE:4737) A Good Fit?

Full year 2020 earnings released: EPS NT$1.06 (vs NT$1.85 in FY 2019)

Bionime Corporation Announces Dividend for the Year 2020

Bionime Corporation, Annual General Meeting, Jun 24, 2021

Did You Participate In Any Of Bionime's (TPE:4737) Respectable 83% Return?

Investor sentiment improved over the past week

Should You Use Bionime's (TPE:4737) Statutory Earnings To Analyse It?

New 90-day low: NT$62.30

Bionime (TPE:4737) Has A Somewhat Strained Balance Sheet

Bionime Corporation Announces Change to the Principal Accounting Officer of the Company

New 90-day low: NT$64.50

How Has Bionime (TPE:4737) Allocated Its Capital?

A Closer Look At Bionime Corporation's (TPE:4737) Uninspiring ROE

A Look At The Fair Value Of Bionime Corporation (TPE:4737)

Bionime Corporation (TPE:4737) Investors Should Think About This Before Buying It For Its Dividend

New 90-day low: NT$68.20

Bionime (TPE:4737) Has Compensated Shareholders With A Respectable 50% Return On Their Investment

Third quarter 2020 earnings released: EPS NT$0.68

First half earnings released

Upcoming Dividend of NT$1.99 Per Share

Previsioni di crescita degli utili e dei ricavi

Previsioni di crescita futura degli analisti

Previsioni di crescita dell'utile per azione

Rendimento futuro del capitale proprio

Scoprire le aziende in crescita